small molecule

ZORYVE

ROFLUMILAST

Loss of exclusivityAugust 2037latest FDA-listed patent expiry

CompanyArcutis Biotherapeutics, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand name	ZORYVE
Active ingredient	ROFLUMILAST
Strength	0.15%
Dosage form	CREAM
Route	TOPICAL
Modality	Small molecule
FDA approval	July 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
11129818	August 2037	use U-3970
11992480	June 2037	use U-3970
11819496	June 2037	use U-3970
12310956	June 2037	use U-3970
9907788	June 2037	use U-3970
12042487	June 2037	product
12016848	June 2037	product
12336983	June 2037	product
12011437	June 2037	product
10940142	June 2037	product
12005052	June 2037	product
12220409	June 2037	product
12257242	June 2037	product
9884050	June 2037	product
12005051	June 2037	use U-3970
11793796	June 2037	product

Regulatory exclusivity

Code	Expires
NS	July 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Arcutis Biotherapeutics, Inc.